ENTPD1 and autoimmune disease: Targeting CD39 and CD73 presents significant clinical potential for various pathological conditions, including cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, infectious diseases, neurological disorders, respiratory diseases, metabolic disorders, and skin diseases.